121 related articles for article (PubMed ID: 38360554)
1. Is MYCN Overexpression Associated With Poor Outcome in
Andrews A; Terry J
Pediatr Dev Pathol; 2024; 27(3):282-283. PubMed ID: 38360554
[No Abstract] [Full Text] [Related]
2. Identification of MYCN non-amplified neuroblastoma subgroups points towards molecular signatures for precision prognosis and therapy stratification.
Hu X; Zhou Y; Hill C; Chen K; Cheng C; Liu X; Duan P; Gu Y; Wu Y; Ewing RM; Li Z; Wu Z; Wang Y
Br J Cancer; 2024 May; 130(11):1841-1854. PubMed ID: 38553589
[TBL] [Abstract][Full Text] [Related]
3. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas.
Westermann F; Muth D; Benner A; Bauer T; Henrich KO; Oberthuer A; Brors B; Beissbarth T; Vandesompele J; Pattyn F; Hero B; König R; Fischer M; Schwab M
Genome Biol; 2008 Oct; 9(10):R150. PubMed ID: 18851746
[TBL] [Abstract][Full Text] [Related]
4. MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the children's oncology group.
Niemas-Teshiba R; Matsuno R; Wang LL; Tang XX; Chiu B; Zeki J; Coburn J; Ornell K; Naranjo A; Van Ryn C; London WB; Hogarty MD; Gastier-Foster JM; Look AT; Park JR; Maris JM; Cohn SL; Seeger RC; Asgharzadeh S; Ikegaki N; Shimada H
Oncotarget; 2018 Jan; 9(5):6416-6432. PubMed ID: 29464082
[TBL] [Abstract][Full Text] [Related]
5. MYCN is the only highly expressed gene from the core amplified domain in human neuroblastomas.
Reiter JL; Brodeur GM
Genes Chromosomes Cancer; 1998 Oct; 23(2):134-40. PubMed ID: 9739016
[TBL] [Abstract][Full Text] [Related]
6. High Skp2 expression characterizes high-risk neuroblastomas independent of MYCN status.
Westermann F; Henrich KO; Wei JS; Lutz W; Fischer M; König R; Wiedemeyer R; Ehemann V; Brors B; Ernestus K; Leuschner I; Benner A; Khan J; Schwab M
Clin Cancer Res; 2007 Aug; 13(16):4695-703. PubMed ID: 17652624
[TBL] [Abstract][Full Text] [Related]
7. Author(s)' Reply: Is MYCN Overexpression Associated With Poor Outcome in
Zhao M; Shu Y; Gu W; Tang H; Mao J
Pediatr Dev Pathol; 2024; 27(3):284-285. PubMed ID: 38360532
[No Abstract] [Full Text] [Related]
8. Whole-tumour apparent diffusion coefficient (ADC) histogram analysis to identify MYCN-amplification in neuroblastomas: preliminary results.
Ghosh A; Yekeler E; Dalal D; Holroyd A; States L
Eur Radiol; 2022 Dec; 32(12):8453-8462. PubMed ID: 35437614
[TBL] [Abstract][Full Text] [Related]
9. Yeast artificial chromosome (YAC) vector cloning of the MYCN amplified domain in neuroblastomas.
Schneider SS; Zehnbauer BA; Vogelstein B; Brodeur GM
Prog Clin Biol Res; 1991; 366():71-6. PubMed ID: 2068181
[TBL] [Abstract][Full Text] [Related]
10. Functional interplay between MYCN, NCYM, and OCT4 promotes aggressiveness of human neuroblastomas.
Kaneko Y; Suenaga Y; Islam SM; Matsumoto D; Nakamura Y; Ohira M; Yokoi S; Nakagawara A
Cancer Sci; 2015 Jul; 106(7):840-7. PubMed ID: 25880909
[TBL] [Abstract][Full Text] [Related]
11. Ability of circular extrachromosomal DNA molecules to carry amplified MYCN proto-oncogenes in human neuroblastomas in vivo.
VanDevanter DR; Piaskowski VD; Casper JT; Douglass EC; Von Hoff DD
J Natl Cancer Inst; 1990 Dec; 82(23):1815-21. PubMed ID: 2250296
[TBL] [Abstract][Full Text] [Related]
12. ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas.
Wang Q; Hii G; Shusterman S; Mosse Y; Winter CL; Guo C; Zhao H; Rappaport E; Hogarty MD; Maris JM
Cancer Res; 2003 Apr; 63(7):1631-5. PubMed ID: 12670915
[TBL] [Abstract][Full Text] [Related]
13. MYCN-status in neuroblastoma: characteristics of tumours showing amplification, gain, and non-amplification.
Spitz R; Hero B; Skowron M; Ernestus K; Berthold F
Eur J Cancer; 2004 Dec; 40(18):2753-9. PubMed ID: 15571958
[TBL] [Abstract][Full Text] [Related]
14. Chromogenic in situ hybridization-detected hotspot MYCN amplification associates with Ki-67 expression and inversely with nestin expression in neuroblastomas.
Korja M; Finne J; Salmi TT; Kalimo H; Karikoski R; Tanner M; Isola J; Haapasalo H
Mod Pathol; 2005 Dec; 18(12):1599-605. PubMed ID: 16258518
[TBL] [Abstract][Full Text] [Related]
15. The coamplification pattern of the MYCN amplicon is an invariable attribute of most MYCN-amplified human neuroblastomas.
Weber A; Starke S; Bergmann E; Christiansen H
Clin Cancer Res; 2006 Dec; 12(24):7316-21. PubMed ID: 17189403
[TBL] [Abstract][Full Text] [Related]
16. E2F proteins regulate MYCN expression in neuroblastomas.
Strieder V; Lutz W
J Biol Chem; 2003 Jan; 278(5):2983-9. PubMed ID: 12438307
[TBL] [Abstract][Full Text] [Related]
17. High-resolution mapping of a 130-kb core region of the MYCN amplicon in neuroblastomas.
Reiter JL; Brodeur GM
Genomics; 1996 Feb; 32(1):97-103. PubMed ID: 8786126
[TBL] [Abstract][Full Text] [Related]
18. Ultrastructural features of neuroblastic tumours in relation to morphological, and molecular findings; a retrospective review study.
Latimer E; Anderson G; Sebire NJ
BMC Clin Pathol; 2014; 14():13. PubMed ID: 24679140
[TBL] [Abstract][Full Text] [Related]
19. The long non-coding RNA MYCNOS-01 regulates MYCN protein levels and affects growth of MYCN-amplified rhabdomyosarcoma and neuroblastoma cells.
O'Brien EM; Selfe JL; Martins AS; Walters ZS; Shipley JM
BMC Cancer; 2018 Feb; 18(1):217. PubMed ID: 29466962
[TBL] [Abstract][Full Text] [Related]
20. CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2.
Chen L; Alexe G; Dharia NV; Ross L; Iniguez AB; Conway AS; Wang EJ; Veschi V; Lam N; Qi J; Gustafson WC; Nasholm N; Vazquez F; Weir BA; Cowley GS; Ali LD; Pantel S; Jiang G; Harrington WF; Lee Y; Goodale A; Lubonja R; Krill-Burger JM; Meyers RM; Tsherniak A; Root DE; Bradner JE; Golub TR; Roberts CW; Hahn WC; Weiss WA; Thiele CJ; Stegmaier K
J Clin Invest; 2018 Jan; 128(1):446-462. PubMed ID: 29202477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
